Mp18-16 Biparametric Mri Performance Is Comparable to Multiparametric Mri for the Accurate Detection of Clinically Significant Prostate Cancer

You have accessJournal of UrologyImaging/Uroradiology I (MP18)1 May 2024MP18-16 BIPARAMETRIC MRI PERFORMANCE IS COMPARABLE TO MULTIPARAMETRIC MRI FOR THE ACCURATE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER Nicholas A. Pickersgill, Alex L. Shiang, Joel M. Vetter, Nimrod Barashi, John Sheng, Joseph E. Ippolito, and Eric H. Kim Nicholas A. PickersgillNicholas A. Pickersgill , Alex L. ShiangAlex L. Shiang , Joel M. VetterJoel M. Vetter , Nimrod BarashiNimrod Barashi , John ShengJohn Sheng , Joseph E. IppolitoJoseph E. Ippolito , and Eric H. KimEric H. Kim View All Author Informationhttps://doi.org/10.1097/01.JU.0001008672.83391.ed.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Multiparametric magnetic resonance imaging (MRI) is the most widely used approach for prostate MRI. While biparametric MRI (BP-MRI) involves shorter acquisition time and decreased cost, its diagnostic accuracy compared to multiparametric MRI (MP-MRI) is not well known. We aim to compare the accurate detection of clinically significant prostate cancer with BP-MRI and MP-MRI prior to biopsy. METHODS: A single-institution retrospective analysis was performed of men who underwent prostate MP-MRI and BP-MRI prior to biopsy between January 2019 and December 2022, interpreted by a single expert radiologist. All patients underwent systematic and targeted transperineal prostate biopsy after MRI. Receiver operating characteristic (ROC) curves were generated to assess the accuracy, sensitivity, and specificity of MP-MRI and BP-MRI using biopsy pathology with Grade Group≥2 disease as the reference standard. RESULTS: In a cohort of 310 patients, 192 underwent MP-MRI and 118 underwent BP-MRI. Suspicious lesions were identified on 63.0% and 46.6% of MP-MRI and BP-MRI, respectively. Area under the curve values for MP-MRI and BP-MRI were 0.75 and 0.80, respectively (p=0.359). Diagnostic accuracy was 67.7% for MP-MRI and 74.6% for BP-MRI (p=0.199). Multivariate analysis revealed no difference in the likelihood of detecting Grade Group ≥2 disease on biopsy following either approach (OR 0.88 0.53-1.45). CONCLUSIONS: BP-MRI and MP-MRI protocols demonstrated comparable predictive accuracy for the detection of clinically significant prostate cancer, suggesting that dynamic contrast enhancement offers limited clinical benefit. BP-MRI should be considered the standard for pre-biopsy imaging in patients with suspected prostate cancer. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e307 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Nicholas A. Pickersgill More articles by this author Alex L. Shiang More articles by this author Joel M. Vetter More articles by this author Nimrod Barashi More articles by this author John Sheng More articles by this author Joseph E. Ippolito More articles by this author Eric H. Kim More articles by this author Expand All Advertisement PDF downloadLoading ...